Combining antihyperglycemic agents in order to rapidly and safely achieve the 
best possible glycemic control is the standard of care today for the management 
of type 2 diabetes. Agents should ideally have mechanisms of actions that are 
complementary and that improve glycemic control without unacceptable gain in 
body weight or hypoglycemia. Areas covered: Ertugliflozin and metformin 
hydrochloride (ertugliflozin/metformin, SEGLUROMET) is a recently approved 
fixed-dose combination tablet containing the sodium-glucose co-transporter 2 
(SGLT-2) inhibitor ertugliflozin and metformin. This review summarizes key 
characteristics of ertugliflozin and metformin, as well as the efficacy and 
safety results of co-administration of these agents in the ertugliflozin 
clinical development program. This information comes from the 
ertugliflozin/metformin prescribing information as well as published clinical 
trials obtained through a PubMed search. Expert commentary: SGLT-2 inhibitors 
are an important class of antihyperglycemic agents that are efficacious as 
monotherapy and in combination with other antihyperglycemic agents. Given their 
favorable effects on glycemia control as well as 'extra-glycemic' parameters 
such as body weight and blood pressure, they are ideal agents for appropriate 
patients with type 2 diabetes. The fixed-dose combination of ertugliflozin with 
metformin is an effective combination that is conveniently administered and may 
improve medication adherence and persistence.